BA
CLMT icon

Bard Associates’s Calumet Specialty Products CLMT Stock Holding History

Bard Associates’s Portfolio CLMT Stock Details CLMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-12,835
Closed -$408K – 172
2014
Q2 		$408K Hold
12,835
– – 0.16% 143
2014
Q1 		$332K Hold
12,835
– – 0.14% 151
2013
Q4 		$334K Buy
12,835
+50
+0.4% +$1.4K 0.14% 151
2013
Q3 		$349K Hold
12,785
– – 0.15% 144
2013
Q2 		$465K Buy
+12,785
New +$460K 0.22% 131

Other funds holding CLMT

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Edge Asset Management Seattle, Washington $13.2B AUM 19.52% 1-Year Est. Return
AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
IMS
Index Management Solutions Philadelphia, Pennsylvania $101M AUM 12.09% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CA
Corrado Advisors Ramsey, New Jersey $192M AUM 20.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Bard Associates's CLMT Position: Q3 2014 in Review

Bard Associates sold out of Calumet Specialty Products (CLMT) in Q3 2014, closing a stake of 12,835 shares — an estimated $408K sold.

Bard Associates first reported a position in CLMT in Q2 2013 and held it in 5 quarters. The position peaked at $465K in Q2 2013. 115 funds tracked by Wall St. Rank hold CLMT as of Q3 2014.

  • Bard Associates reported no remaining Calumet Specialty Products position as of Q3 2014 after selling out during the quarter.
  • Bard Associates sold 12,835 Calumet Specialty Products shares in Q3 2014, an estimated $408K.
  • Bard Associates first reported a position in Calumet Specialty Products in Q2 2013 and held it in 5 quarters.
  • Bard Associates's Calumet Specialty Products position peaked at $465K in Q2 2013.
  • 115 funds tracked by Wall St. Rank held Calumet Specialty Products as of Q3 2014.

Based on Bard Associates's 13F filing for Q3 2014, filed 13 Nov 2014.